HistoSonics Edison system gains early market access in the U.K.

The histotripsy procedure. | Source: Screenshot taken from a HistoSonics video

HistoSonics announced last week that its Edison histotripsy system for noninvasively destroying liver tumors has secured limited U.K. market access.

According to the Plymouth, Minn.–based company, the Medicines and Healthcare Products Regulatory Agency in Great Britain granted controlled early limited market access under an Unmet Clinical Need Authorisation available through the U.K.’s Innovative Devices Access Pathway (IDAP) program.